ABVX Abivax Corp: מכפיל P/S עתידי

Investing in ABIVAX (ABVX) carries the critical risk of final drug trial failures and a rapid cash burn. The forward P/S trajectory visualizes market expectations, where the current level equals . While demand for intestinal inflammation therapies remains colossal, business success is dictated by regulatory verdicts rather than general economic trends or GDP dynamics.

The selection of defensive assets is based on identifying companies with fundamental growth potential, which at ABIVAX (ABVX) is driven by a concentration of leading immunologists and large-scale funding for breakthrough developments. By analyzing the forward price-to-sales multiple chart, an investor assesses the ratio of market demand to expected annual sales, where high line volatility signals the potential for excess profits alongside a significant risk of deep price corrections.